AstraZeneca lung and breast cancer data at WCLC and ESMO 2021 underscore ambition to revolutionise outcomes for patients

2 September 2021 07:00 BST

Enhertu demonstrates transformative progression-free survival in HER2-positive metastatic breast cancer; data in lung and gastric cancers show strong efficacy across HER2-targetable tumours

 Multiple trials reinforce the efficacy of Imfinzi combinations, including with novel immunotherapies, for lung cancer patients across settings

AstraZeneca will present new data across its diverse portfolio of cancer medicines at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress 2021.

A total of 14 approved and potential new medicines from AstraZeneca will be featured across more than 100 abstracts at the two meetings. There will be five oral presentations including one Presidential Symposium at WCLC, hosted by the IASLC between 8 and 14 September. A total of 20 oral presentations including one Presidential Symposium will be featured at ESMO between 16 and 21 September.

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: “Imfinzi and Tagrisso have redefined outcomes for patients with lung cancer, becoming the established standards of care around the world in certain settings. Our data at WCLC and ESMO illustrate our commitment to building on the benefits of these medicines with novel combinations to extend them to more patients. Our data will also showcase the real-world impact of these medicines in clinical practice.”

Susan Galbraith, Executive Vice President, Oncology R&D said: “The DESTINY-Breast03 data at ESMO will demonstrate the potential for Enhertu to transform the treatment of HER2-positive metastatic breast cancer with a safety profile that supports the potential for Enhertu in early-stage disease. Additionally, the data from COAST will support our aim to extend the benefit of Imfinzi in unresectable, Stage III non-small cell lung cancer by combining it with potential first-in-class immunotherapies. Also, new data on Lynparza will answer critical questions about retreatment with a PARP inhibitor in resistant disease.”

Leading in lung cancer with established standards of care and novel combination
A Presidential Symposium will present results from the final analysis of the POSEIDON Phase III trial at WCLC showing a significant, clinically meaningful survival benefit for the combination of Imfinzi (durvalumab), tremelimumab and chemotherapy in metastatic non-small cell lung cancer (NSCLC).

A late-breaking presentation at ESMO will feature three-year overall survival (OS) data from the CASPIAN Phase III trial of Imfinzi in extensive-stage small cell lung cancer (ES-SCLC), the longest reported to date for a Phase III trial of chemotherapy and PD-1/PD-L1 immunotherapy in this disease setting. Imfinzi is the only PD-1/PD-L1 immunotherapy to demonstrate both a significant survival benefit and improved response rate in combination with a choice of chemotherapies in ES-SCLC.

In another late-breaking presentation at ESMO, the COAST Phase II trial will highlight progression-free survival (PFS) results for novel Imfinzi combinations with potential new medicines including oleclumab, an anti-CD73 monoclonal antibody, and monalizumab, an anti-NKG2A monoclonal antibody, in unresectable, Stage III NSCLC, building on the PACIFIC Phase III trial results that established Imfinzi as the standard of care in this setting.

Data at ESMO will showcase research into combatting resistant disease, including interim results from the ORCHARD Phase II trial studying the combination of Tagrisso (osimertinib) and savolitinib, an oral, potent and highly selective MET tyrosine kinase inhibitor, in patients with advanced EGFR-mutated (EGFRm) NSCLC with MET alterations whose disease progressed on 1st-line Tagrisso.

Real-world data will provide new compelling evidence for the efficacy and safety profiles of Imfinzi and Tagrisso in NSCLC. At ESMO, PFS and tolerability data will be shared from the PACIFIC-R global observational study of patients with unresectable, Stage III NSCLC treated with Imfinzi after chemoradiation therapy. At WCLC, an interim analysis from the US cohort of a global prospective study will reinforce the efficacy of 1st-line Tagrisso in a real-world population of patients with EGFRm NSCLC.

Transforming treatment of advanced cancers with antibody drug conjugates (ADCs)
At ESMO, a Presidential Symposium will present the results from the DESTINY-Breast03 Phase III trial demonstrating the potentially transformative impact of Enhertu (trastuzumab deruxtecan) for patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. DESTINY-Breast03 is the first global Phase III trial of Enhertu against an active control. In August 2021, the Independent Data Monitoring Committee recommended unblinding the trial based on a planned interim analysis showing a highly statistically significant and clinically meaningful improvement in the primary endpoint of PFS versus trastuzumab emtansine (T-DM1).

Also at ESMO, data will include updated OS data from the DESTINY-Breast01 Phase II trial in HER2-positive metastatic breast cancer and late-breaking results from the DESTINY-Gastric02 Phase II trial in HER2-positive metastatic gastric cancer. A late-breaking presentation will feature primary analysis results from the HER2-mutant cohort of the DESTINY-Lung01 Phase II trial investigating Enhertu in patients with HER2-mutated metastatic NSCLC who have progressed following one or more systemic therapies, a setting where there are currently no approved HER2-directed treatments.

Updated data from the advanced/metastatic NSCLC cohort in the TROPION-PanTumor01 Phase I trial of datopotamab deruxtecan (Dato-DXd) will be presented at WCLC in a mini-oral presentation, and new NSCLC sub-analysis data will be shared in a late-breaking presentation at ESMO highlighting clinical activity in patients whose tumours have actionable genomic alterations. There are currently no TROP2-directed medicines approved for NSCLC, a setting where Dato-DXd has shown promising results in Phase I trials.

Changing treatment paradigms with industry-leading PARP inhibitors and next-wave DNA damage response therapies
At ESMO, late-breaking data will be presented from the OReO/ENGOT Ov-38 Phase IIIb trial testing maintenance retreatment with Lynparza (olaparib) in patients with platinum-sensitive, relapsed epithelial ovarian cancer. OReO is the first Phase III trial to evaluate retreatment with a PARP inhibitor in resistant disease. Another presentation will feature subgroup analyses and updated safety data from the POLO Phase III trial of Lynparza in germline BRCA-mutated metastatic pancreatic cancer, a disease in which no other PARP inhibitor is approved.

An oral presentation will share interim data from an externally sponsored Phase II trial with ceralasertib, an ataxia telangiectasia and rad3-related (ATR) kinase inhibitor, testing anti-tumour activity in patients with ARID1A-deficient and -intact solid tumours.

Collaboration in the scientific community is critical to improving outcomes for patients. AstraZeneca is collaborating with MSD (Merck & Co., Inc. in the US and Canada) to develop and commercialise Lynparza; with Daiichi Sankyo Company, Limited (Daiichi Sankyo) to develop and commercialise Enhertu and Dato-DXd, and with HUTCHMED to develop and commercialise savolitinib. AstraZeneca obtained full oncology rights to monalizumab from Innate Pharma in October 2018 through a co-development and commercialisation agreement initiated in 2015.

AstraZeneca to host virtual event on 15 September: “Spotting cancer before it has a chance: Can screening become universal?
To highlight diverse viewpoints on universal cancer screening, the Company will host a virtual event in collaboration with the European Alliance for Personalised Medicine on 15 September, 14:00 CEST. The event will bring together experts across disciplines to discuss the future of cancer screening and the barriers that persist to making screening universal. Registration for the event is open to the public.

Key AstraZeneca presentations during IASLC WCLC 20211

Lead author

Abstract title

Presentation details


Garassino, MC

Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN

Abstract #MA16.06

Mini Oral Session: MA16 – SCLC: New Targets, Biomarkers, and Systemic Therapies

13 September 2021

20:35 – 20:40 MDT

14 September 2021

3:35 – 3:40 BST

Johnson, ML

Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

Abstract #PL02.01

Plenary: PL02 – Plenary 2: Presidential Symposium

9 September 2021

6:30 – 6:40 MDT

13:30 – 13:40 BST

Tumour drivers and resistance

Blakely, CM

A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results

Abstract #P26.02

Posters: P26 – Locally Advanced Non-Small Cell Lung Cancer – EGFR Targeted Therapy

8 September 2021

Nieva, J

Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib

Abstract #P48.17

Posters: P48 – Novel Therapeutics and Targeted Therapies – EGFR

8 September 2021

Sequist, LV

COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib

Abstract #P47.11

Posters: P47 – Novel Therapeutics and Targeted Therapies – Clinical Trial in Progress

8 September 2021

Antibody drug conjugates

Borghaei, H

TROPION-Lung04: Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab and Platinum-Based Chemotherapy in Advanced NSCLC

Abstract #P47.06

Posters: P47 – Novel Therapeutics and Targeted Therapies – Clinical Trial in Progress

8 September 2021

Garon, EB

TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors

Abstract #MA03.02

Mini Oral Session: MA03 – Biomarkers for Immunotherapy: Are All Relevant?

8 September 2021

10:50 – 10:55 MDT

17:50 – 17:55 BST

Johnson, ML

A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)

Abstract: #P47.05

Posters: P47 – Novel Therapeutics and Targeted Therapies – Clinical Trial in Progress

8 September 2021

Levy, B

TROPION-Lung02: Datopotamab Deruxtecan (Dato-DXd) Plus Pembrolizumab and Platinum-Based Chemotherapy in Advanced NSCLC

Abstract #P47.04

Posters: P47 – Novel Therapeutics and Targeted Therapies – Clinical Trial in Progress

8 September 2021

1 22 abstracts at IASLC WCLC 2021 will feature AstraZeneca medicines and pipeline molecules.

Key AstraZeneca presentations during ESMO Congress 2021

Lead author

Abstract title

Presentation details


Girard, N

PACIFIC-R Real-World Study: Treatment Duration and Interim Analysis of Progression-Free Survival in Unresectable Stage III NSCLC Patients Treated with Durvalumab After Chemoradiotherapy

Abstract #1171MO

Mini Oral session – Non-metastatic NSCLC and other thoracic malignancies

18 September 2021

17:55 – 18:00 CEST

16:55 – 17:00 BST

Martinez-Marti, A

COAST: an open-label, phase 2, multidrug platform study of durvalumab alone or in combination with novel agents in patients with unresectable, Stage III NSCLC

Abstract #LBA42

Proffered Paper session – Non-metastatic NSCLC and other thoracic malignancies

17 September 2021

14:20 – 14:30 CEST

13:20 – 13:30 BST

Paz-Ares, L

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 36-month overall survival from the Phase 3 CASPIAN study

Abstract #LBA61

Mini Oral session – Non-metastatic NSCLC and other thoracic malignancies

18 September 2021

18:10 – 18:15 CEST

17:10 – 17:15 BST

Tumour drivers and resistance

Cheema, P

Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial

Abstract #1165P


Hamilton, E

CAPItello-292: a phase 1b/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+/HER2-advanced breast cancer

Abstract #338TiP


Yu, H

ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed Phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

Abstract #1239P


Antibody drug conjugates


Saura, C

Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (MBC): Updated Survival Results from a Phase 2 Trial (DESTINY-Breast01)

Abstract #279P


Cortés, J

Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer (mBC): Results of the Randomized Phase 3 DESTINY-Breast03 Study

Abstract #LBA1

Presidential symposium 1

18 September 2021

15:05 – 15:20 CEST

14:05 – 14:20 BST

Van Cutsem, E

Primary Analysis of a Phase 2 Single-Arm Trial of Trastuzumab Deruxtecan (T-DXd) in Western Patients (Pts) With HER2-Positive (HER2+) Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Cancer Who Progressed on or After a Trastuzumab-containing Regimen

Abstract #LBA55

Mini oral session – Gastrointestinal tumours, non-colorectal

17 September 2021

17:45 – 17:50 CEST

16:45 – 16:50 BST

Li, BT

Primary Data from DESTINY-Lung01: A Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Mutated (HER2m) Metastatic Non–Small Cell Lung Cancer (NSCLC)

Abstract #LBA45

Proffered Paper session – NSCLC, metastatic 1

18 September 2021

14:00 – 14:10 CEST

13:00 – 13:10 BST

Garon, EB

Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): preliminary results from the phase 1 TROPION-PanTumor01 study

Abstract #LBA49

Mini oral session – NSCLC, metastatic

19 September 2021

17:30 – 17:35 CEST

16:30 – 16:35 BST

DNA damage response

Pujade-Lauraine, E

Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

Abstract #LBA33

Proffered Paper session – Gynaecological cancers

17 September 2021

14:20 – 14:30 CEST

13:20 – 13:30 BST

Aggarwal, R

Interim results from a phase 2 study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies

Abstract #512O

Proffered Paper session – Developmental therapeutics

17 September 2021

13:40 – 13:50 CEST
12:40 – 12:50 BST

Lindemann, K

Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): exploratory biomarker analyses of the Phase IIIb OPINION study

Abstract #740P


Sabatier, R

Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts)aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial

Abstract #739P


Schweizer, MT

Bipolar Androgen Therapy (BAT) plus Olaparib in Men with Metastatic Castration-resistant Prostate Cancer (mCRPC)

Abstract #592P


1 88 abstracts at ESMO Congress 2021 will feature AstraZeneca medicines and pipeline molecules.

AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.

For details on how to contact the Investor Relations Team, please click here. For media contacts, click here.


  • Corporate and financial